Classification of Mucin-Type -Glycopeptides Using Higher-Energy Collisional Dissociation in Mass Spectrometry
Affiliations
Changes in mucin-type -glycosylation of human proteins affect protein function, immune response, and cancer progression. Since -glycoproteins are characterized by the microheterogeneity of diverse -glycans with no conserved sequence and the macroheterogeneity of multiple glycosylation sites on serine and/or threonine in human proteins, the assessment of different mucin types, such as Tn-antigen, core 1, and core 2, and their extended core types in -glycopeptides, is extremely challenging. Here, we present an (-GPA) that automatically classifies mucin-type -glycosylation using higher-energy collisional dissociation (HCD) in mass spectrometry. First, we estimated the number of GlcNAc residues using the intensity ratio of GlcNAc-specific fragment ions (HexNAc-CHO and HexNAc-2HO) over GalNAc-specific fragment ions (HexNAc-CHO and HexNAc-CHO) in the HCD spectrum. Furthermore, we classified the different mucin types of -glycopeptides from characteristic B (HexNAc) or Y (PEP + HexNAc), and Y (PEP + HexNAcHex) fragment ions, along with the number of GlcNAc. Furthermore, -GPA automatically determined single or multiple -glycosylation, regardless of the mucin types. The mucin type of -glycopeptides from human urine and plasma was confirmed with an overall accuracy of 96%. We found 97 core 1, 56 core 2, 13 extended core 1, and 12 extended core 2 glycopeptides from urine; and 22 core 1, 13 core 2, 7 extended core 1, 1 extended core 2, and 1 Tn-antigen from plasma. Our strategy can be used to successfully characterize specific mucin types of -glycoproteins in human biological samples.
Song J, Jang S, Choi J, Hwang S, Kim K, Kim H Int J Mol Sci. 2025; 25(24.
PMID: 39769415 PMC: 11678118. DOI: 10.3390/ijms252413649.
O-Glycoproteomics Sample Preparation and Analysis Using NanoHPLC and Tandem MS.
Wang J, Onigbinde S, Purba W, Nwaiwu J, Mechref Y Methods Mol Biol. 2024; 2762:281-290.
PMID: 38315372 PMC: 11770557. DOI: 10.1007/978-1-0716-3666-4_17.
Li S, Zhu J, Lubman D, Zhou H, Tang H J Proteome Res. 2023; 22(5):1501-1509.
PMID: 36802412 PMC: 10164058. DOI: 10.1021/acs.jproteome.3c00066.
Advanced assessment through intact glycopeptide analysis of Infliximab's biologics and biosimilar.
Kim H, Bang G, Park Y, Park M, Choi J, Oh M Front Mol Biosci. 2022; 9:1006866.
PMID: 36523652 PMC: 9745114. DOI: 10.3389/fmolb.2022.1006866.
Escobar E, Wang S, Goswami R, Lanzillotti M, Li L, McLellan J Anal Chem. 2022; 94(15):5776-5784.
PMID: 35388686 PMC: 9272412. DOI: 10.1021/acs.analchem.1c04874.